GlassScriptPhysician profile
Mohammad Z Amin
NPI 1851325534
$5,123.57
in general payments reported to CMS, 2019-2025
19 companies · $1,734 in 2025
The $1,734 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,177 · 2020: $98.57 · 2021: $177 · 2022: $118 · 2023: $795 · 2024: $1,024 · 2025: $1,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,513 · Education: $39.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,512.62 |
| Education | $39.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $888.64 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $738.54 | 2019-2025 | Farxiga, Lokelma, Flumist Quadrivalent |
| Fresenius USA Marketing, INC. | $701.36 | 2019-2025 | Liberty Select Cycler, Nxstage System One, Velphoro |
| Vifor Pharma, INC. | $585.18 | 2019-2025 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $443.16 | 2022-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $432.65 | 2019-2025 | Jynarque, Voyxact |
| Mallinckrodt Enterprises LLC | $333.53 | 2019 | |
| Calliditas Therapeutics US INC. | $215.63 | 2023-2025 | Tarpeyo |
| Baxter Healthcare | $143.38 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $133.75 | 2024-2025 | |
| Vantive US Healthcare LLC | $117.17 | 2025 | Renal - Pd |
| Outset Medical INC | $108.31 | 2023 | |
| Amgen INC. | $94.14 | 2020-2025 | Tavneos |
| Opko Pharmaceuticals, LLC | $61.26 | 2019-2021 | |
| Akebia Therapeutics INC | $35.11 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $32.59 | 2024-2025 | Ibsrela |
| Scpharmaceuticals INC. | $22.54 | 2025 | |
| Astellas Pharma US INC | $20.05 | 2021 | |
| Horizon Therapeutics Plc | $16.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.